Researchers at Stanford have developed synthetic derivatives of a natural product, azapodophyllotoxin (AZP), that exhibit remarkable anticancer activities.
Researchers at Stanford have developed methods to identify and treat MYC-driven cancers, including renal cell carcinoma (RCC). RCC is a common, aggressive type of kidney cancer and effective therapeutics are lacking.